|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of glucose-1-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucose-1-phosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:101,243,146...101,247,323
Ensembl chr10:101,235,994...101,247,337
|
|
|
G |
App |
amyloid beta precursor protein |
decreases abundance multiple interactions |
ISO |
APP protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glucose-6-Phosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:33179799 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
increases hydrolysis |
ISO |
G6PC2 protein results in increased hydrolysis of Glucose-6-Phosphate |
CTD |
PMID:14722102 |
|
NCBI chr 3:53,999,821...54,005,539
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
ISO |
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of Glucose-6-Phosphate] |
CTD |
PMID:31974165 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions decreases abundance |
ISO |
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate] MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA |
CTD |
PMID:20505214 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Pfkfb1 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 |
increases abundance multiple interactions |
ISO |
PFKFB1 gene mutant form results in increased abundance of Glucose-6-Phosphate PFKFB1 gene mutant form inhibits the reaction [Metformin results in decreased abundance of Glucose-6-Phosphate metabolite] |
CTD |
PMID:31974165 |
|
NCBI chr X:19,508,522...19,562,165
Ensembl chr X:19,508,546...19,562,182
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate |
CTD |
PMID:31974165 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] |
CTD |
PMID:39172838 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
ISO |
mannose-6-phosphate affects the reaction [GUSB protein affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] |
CTD |
PMID:26438400 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
multiple interactions decreases activity |
EXP |
EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of ECE1 protein] phosphoramidon decreases activity of recombinant Ece1 protein in COS cells |
CTD RGD |
PMID:11145282 PMID:16280098 PMID:8034569 |
RGD:728596 |
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
EXP |
phosphoramidon results in decreased expression of EDN1 protein EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein] |
CTD |
PMID:11145282 PMID:16280098 PMID:16391412 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]; phosphoramidon inhibits the reaction [Phenylephrine results in increased expression of EDNRA protein] |
CTD |
PMID:15007106 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
phosphoramidon results in increased expression of EDNRB protein |
CTD |
PMID:15007106 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:15177934 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of ICAM1 protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Kel |
Kell metallo-endopeptidase (Kell blood group) |
multiple interactions |
ISO |
KEL protein alternative form binds to and affects the metabolism of phosphoramidon |
CTD |
PMID:15769748 |
|
NCBI chr 4:70,568,241...70,585,666
Ensembl chr 4:70,568,243...70,585,631
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
phosphoramidon results in decreased expression of LEP protein |
CTD |
PMID:16391412 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15177934 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in increased activity of MME protein] |
CTD |
PMID:10070497 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15177934 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Sell |
selectin L |
multiple interactions |
EXP |
phosphoramidon inhibits the reaction [Morphine results in decreased expression of SELL protein alternative form] |
CTD |
PMID:10070497 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
[TAC1 protein co-treated with phosphoramidon] results in increased uptake of Oxygen |
CTD |
PMID:9808699 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|